Literature DB >> 9676572

What have snakes taught us about integrins?

T F Huang1.   

Abstract

Snake venoms contain unique components that affect cell-matrix interactions. Disintegrins represent a class of low molecular weight, Arg-Gly-Asp (RGD)-containing, cysteine-rich peptides purified from the venom of various snakes among the Viperidae and Crotalidae. They bind with various degrees of specificity to integrins alpha IIb beta 3, alpha 5 beta 1 and alpha V beta 3 expressed on cells. Snake venom metalloproteases (high molecular mass haemorrhagins) also contain disintegrin-like domains, in addition to zinc-chelating sequences. Membrane-anchored ADAMs (A Disintegrin And Metalloprotease domain), multidomain molecules consisting of metalloprotease, disintegrin-like, cysteine-rich, and epidermal growth factor domains, a transmembrane domain and a cytoplasmic tail, are a new family of proteins. In the light of the large number and wide distribution of ADAMs, they may participate in cell-cell fusion events, including sperm-egg binding and fusion, myoblast fusion and other cell-cell and cell-matrix interactions. The structure-function relationship of these molecules is discussed.

Mesh:

Substances:

Year:  1998        PMID: 9676572     DOI: 10.1007/s000180050181

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  19 in total

Review 1.  AmpA, a modular protein containing disintegrin and ornatin domains, has multiple effects on cell adhesion and cell fate specification.

Authors:  Daphne D Blumberg; Hoa N Ho; Chere' L Petty; Timothy R Varney; Srilatha Gandham
Journal:  J Muscle Res Cell Motil       Date:  2002       Impact factor: 2.698

2.  Biochemical analysis of the molecular mechanism of action of natural integrin inhibitors.

Authors:  A Scibelli; S Tafuri; E Alimenti; M A Belisario; R Della Morte; N Staiano
Journal:  Vet Res Commun       Date:  2003-09       Impact factor: 2.459

3.  Integrin alpha(v)beta(3)-Targeted Cancer Therapy.

Authors:  Zhaofei Liu; Fan Wang; Xiaoyuan Chen
Journal:  Drug Dev Res       Date:  2008       Impact factor: 4.360

4.  Positional importance of Pro53 adjacent to the Arg49-Gly50-Asp51 sequence of rhodostomin in binding to integrin alphaIIbbeta3.

Authors:  C P Chang; J C Chang; H H Chang; W J Tsai; S J Lo
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

5.  Multiple non-catalytic ADAMs are novel integrin α4 ligands.

Authors:  Lei Wang; Jason A Hoggard; Erica D Korleski; Gideon V Long; Brandy C Ree; Kenneth Hensley; Stephen R Bond; Tyra G Wolfsberg; JianMing Chen; Tonya N Zeczycki; Lance C Bridges
Journal:  Mol Cell Biochem       Date:  2017-09-14       Impact factor: 3.396

6.  Treatment with BB-94, a broad spectrum inhibitor of zinc-dependent metalloproteinases, causes deviation of the cytokine profile towards type-2 in experimental pulmonary tuberculosis in Balb/c mice.

Authors:  R Hernandez-Pando; H Orozco; K Arriaga; L Pavön; G Rook
Journal:  Int J Exp Pathol       Date:  2000-06       Impact factor: 1.925

7.  ADAM disintegrin-like domain recognition by the lymphocyte integrins alpha4beta1 and alpha4beta7.

Authors:  Lance C Bridges; Dean Sheppard; Ron D Bowditch
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

8.  Pharmacological characterization and antithrombotic effect of agkistin, a platelet glycoprotein Ib antagonist.

Authors:  C H Yeh; M C Chang; H C Peng; T F Huang
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

9.  A novel family of RGD-containing disintegrins (Tablysin-15) from the salivary gland of the horsefly Tabanus yao targets αIIbβ3 or αVβ3 and inhibits platelet aggregation and angiogenesis.

Authors:  D Ma; X Xu; S An; H Liu; X Yang; J F Andersen; Y Wang; F Tokumasu; J M C Ribeiro; I M B Francischetti; R Lai
Journal:  Thromb Haemost       Date:  2011-04-07       Impact factor: 5.249

10.  The disintegrin, trimucrin, suppresses LPS-induced activation of phagocytes primarily through blockade of NF-κB and MAPK activation.

Authors:  Yu-Chun Hung; Chun-Chieh Hsu; Ching-Hu Chung; Tur-Fu Huang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-03-31       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.